Megan Yung

Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington.

Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ.

Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA.

X-BODY, Inc. provides biotechnological research services. The company was founded on April 9, 2009 and is headquartered in Waltham, MA.

BBK Ltd. provides finance, strategy, operations and general managements consultancy services. It provides finance, strategy, operations and general management consultancy services that monitor the growth, profits and stability of its clients. The company's clients include corporations, mid-sized companies, financial institutions, law firms and private equity firms. BBK was founded by B.N. Bahadur in 1977 and is headquartered in Southfield, MI.

Berenson & Co, Inc. is a merchant bank that was founded in 1990. The private company is based in New York, NY and has subsidiaries in the United States. The company has two principal lines of business which are investment banking and private equity investing. The company was founded by Robb Eric Turner and Jeffrey L. Berenson. Jeffrey L. Berenson has been the CEO since incorporation.

The YMCA of Greater Boston, Inc. provides social services. The firm offers youth development, healthy living and social responsibility services. It conducts pre-K, youth, teen, adult., family programs and provides early education care services. The company was founded in 1851 and is headquartered in Boston, MA.

Upstate New York Power Producers, Inc. owns and operates coal-fired power plants. The company is headquartered in Lansing, NY.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

SSI Strategy owns and operates boutique management consulting firm. Its services include global medical affairs transformation, competency model development, post-merger integration, launch preparation, emerging markets medical affairs: organizational transformation, pharmacovigilance system enhancement and medical planning and tactic prioritization. The company was founded by Gregory Fiore in 2010 and is headquartered in Parsippany, NJ.

Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA.

Sollis Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing novel non-steroid and non-opioid analgesics. The company was founded by Gregory Fiore and Bryan Jones and is headquartered in Columbus, OH.

Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million.

Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA.

Psy Therapeutics, Inc. develops novel medicines for central nervous system disorders. The firm focuses on anxiety, depression and dementia. The company was founded by Brant Binder, Maurizio Fava, Roy Perlis and Jerry Rosenbaum and is headquartered in Boston, MA.

Zebiai Therapeutics, Inc. develops artificial intelligence to predict and optimize novel small molecule modulators for challenging drug targets. The company was founded by Richard Wagner and is headquartered in Chestnut Hill, MA.

Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million.

Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd.

Part of SSI Strategy LLC, Fiore Healthcare Advisors, Inc. provides pharmacovigilance and clinical research consulting services. The company is based in Boston, MA. The company was founded by Gregory Fiore. Fiore Healthcare Advisors was acquired by SSI Strategy LLC on June 29, 2021.

Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million.

X-Chem, Inc. operates as a biotechnology company. Its uses its DEX DNA encoded libraries and platform to discover small molecule leads against high-value therapeutic targets. The company was founded by Richard W. Wagner, Brant C. Binder, Matthew A. Clark, and Gordon M. Binder in 2009 and is headquartered in Waltham, MA.